Rhythm Pharmaceuticals, Inc. RYTM Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of $448K in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash increased by 22500.0% year-over-year, from -$2K to $448K.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
- Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash has grown at a -21.7% compound annual growth rate (CAGR), from -$142K to $87K.